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Abstract
Diverse internal and external pathologic stimuli can trigger cellular stress 
response pathways (CSRPs) that are usually counteracted by intrinsic homeostatic 
machinery, which responds to stress by initiating complex signaling mechanisms 
to eliminate either the stressor or the damaged cells. There is growing evidence 
that CSRPs can have context-dependent homeostatic or pathologic functions that 
may result in tissue fibrosis under persistence of stress. CSRPs can drive intercel-
lular communications through exosomes (trafficking and secretory pathway 
determinants) secreted in response to stress-induced proteostasis rebalancing. The 
injured tissue environment upon sensing the stress turns on a precisely orchestrated 
network of immune responses by regulating cytokine-chemokine production, 
recruitment of immune cells, and modulating fibrogenic niche and extracellular 
matrix (ECM) cross-talk during fibrotic pathologies like cardiac fibrosis, liver 
fibrosis, laryngotracheal stenosis, systemic scleroderma, interstitial lung disease 
and inflammatory bowel disease. Immunostimulatory RNAs (like double stranded 
RNAs) generated through deregulated RNA processing pathways along with RNA 
binding proteins (RBPs) of RNA helicase (RNA sensors) family are emerging as 
important components of immune response pathways during sterile inflammation. 
The paradigm-shift in RNA metabolism associated interactome has begun to offer 
new therapeutic windows by unravelling the novel RBPs and splicing factors in 
context of developmental and fibrotic pathways. We would like to review emerging 
regulatory nodes and their interaction with CSRPs, and tissue remodeling with 
major focus on cardiac fibrosis, and inflammatory responses underlying upper 
airway fibrosis.
Keywords: extracellular matrix, homeostasis, tissue repair, fibrosis, cellular stress, 
RNA binding proteins, RNA interactome
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1. Introduction
Fibrosis is an inherent reparative response invoked to restore tissue integrity 
following a pathologic insult, which metamorphoses into a devastating pathol-
ogy culminating in scars due to self-catenating heralding inflammatory loops. 
Regeneration is a fundamental biological process initiated to orderly replace the 
damaged tissues, however, deregulation of chronic inflammation, growth factor-
receptor cross-talk, intra-intercellular communication, and various extracellular 
matrix proteins eventually result in an aberrant wound healing response marked by 
fibrosis or scarring. Excessive scarring can obliterate tissue architecture, culminat-
ing in organ failure and death. Therefore, lack of coordination and synchronization 
in molecular and cellular events that guide “regeneration” results in “degeneration” 
of the affected organ. Fibroproliferative disorders are widely occurring and include 
pulmonary fibrosis, systemic sclerosis, liver cirrhosis, cardiovascular disease, pro-
gressive kidney disease, corneal scarring, proliferative vitreoretinopathy and pos-
terior capsular opacification. Aberrant tissue remodeling marked by fibrosis is also 
implicated in cancer metastasis and chronic graft rejection in transplant recipients. 
The obvious deprecating impacts of fibrosis are enormous deterrents to patients; 
moreover, the disease has failed to meet the required treatments till date. Lack of 
availability of desired therapeutic interventions is majorly due to an incomplete 
understanding of the mechanism of the disease, therefore, gaining insights into the 
mechanistic pathways of fibrosis would facilitate improved therapeutic approaches 
to target novel mediators besides the cryptic or altered ECM components as previ-
ously reported by our group [1–5].
TGF-β is a central node in driving fibrotic pathways and other diseases, how-
ever, targeting TGF-β pathways has not met desirable clinical success, perhaps 
due to the incomplete mechanistic information on its role in development and 
pathology. Therefore, gaining insights into regulation of TGF-β during normal 
development and pathology could facilitate recognition of alternate target-
pathways that may spare or minimally perturb the role of TGF-β in physiology. 
An interesting and relatively less explored theme is involvement and regulation 
of TGF-β isoforms in fetal wound healing that is marked by absence of scar. 
Intriguingly, there are common mediators and unifying pathways that underlie 
tissue repair, homeostasis and fibrosis in diverse organs; therefore, harnessing 
the potential non-fibrotic themes from scarless wound healing might add to the 
understanding of challenging fibrotic disorders. A systematic and meticulous 
re-assessment and re-evaluation of the role of mediators of scarlessly healing 
wounds might offer a reasonably potential tool to be manipulated to prevent 
fibrosis and decode the invisible lines dividing the “homeostasis-tissue repair-
fibrosis continuum”.
Interestingly, there are few physiological paradigms where wounds heal scar-
lessly or with minimal scarring, for instance the wounds in the early gestation fetus 
and in the oral mucosa of mammals heal without scar [6] the transition from scar-
less to scarred healing occurs in humans during late weeks of gestation [7]. A recent 
study showed that dermal fibroblasts with a scarring phenotype when transplanted 
into oral mucosa ended up generating more scar-like connective tissue compared 
with oral mucosal fibroblasts transplanted into the dermis [8]. The oral mucosal 
fibroblasts were shown to possess a higher baseline production capacity of several 
ECM-associated proteins than the skin fibroblasts, except type III collagen, which 
could be possibly attributed to a more favorable wound healing in oral mucosa [9]. 
Healthy endometrium heals scarlessly and is suggestive of regenerative healing and 
can be paralleled to fetal-like scarless healing responses that are also seen in the 
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buccal mucosa of the oral cavity. Endometrial repair involves highly orchestrated 
cross-stalk in stromal, epithelial, vascular, and immune cells and presents a remark-
able epitome of healing that involves over 400 cycles of resolution of inflammation, 
angiogenesis, tissue remodeling, and formation of new tissue without any residual 
scarring [10]. Recently, neutrophil gelatinase-associated lipocalin, follistatin like-1, 
chemokine ligand-20, and secretory leukocyte protease inhibitor were identified as 
important signatures in menstrual fluid that were proposed to facilitate scar-free 
repair [11]. Endometrial stromal cells were shown to exhibit distinct phenotypic 
and immunomodulatory profiles and displayed lack of HLA class II that was pro-
posed to drive their physiological roles in tissue repair and immune tolerance during 
pregnancy [12].
Psoriasis represents a unique form of “scarless-like or hyper-regenerative” 
wound healing marked by nonscarring, inflammatory, and hyperproliferative 
tissue repair responses. An amazing aspect about the psoriatic lesions is the fact 
that with appropriate therapy the complex skin lesions can be reverted back 
to healthy appearing skin, with little if any evidence of altered changes in the 
epidermis and dermis. Psoriatic plaques are exciting conundrums as they do not 
go to fibrosis even amidst heralding auto-inflammatory loops [13]. An interest-
ing common mediator oncofetal fibronectin extra domain B (Fn-EDB), has been 
reported to be prominent in psoriatic lesions and wound healing in fetal tissue 
[14]. Interestingly, psoriatic plaques despite being vulnerable to infections, do 
not tend to get infected because of the presence of massive antimicrobial peptides 
like LL37. Psoriasis pathogenesis involves strong polymorphonuclear neutrophil 
(PMN) infiltration and high levels of the PMN associated antimicrobial peptide, 
LL37. Psoriasis is marked by self-reactive inflammatory loops of innate immune 
responses, which trigger subsequent adaptive immune responses against auto-
antigens like LL-37, ADAMTSL5, and HNRNPA1, with LL-37 and HNRNPA1 
having RNA-binding properties. The phenomenon of self-RNA sensing by nucleic 
acid sensors [15–17] is central to autoinflammatory and autoimmune diseases 
like psoriasis, however, the role of RNA-binding proteins LL37 and HNRNPA1 
(the proven autoantigens) in contributing to inflammatory loops remains largely 
unexplored. In a psoriatic mice model study excessive polyamine generation was 
shown to facilitate self-RNA sensing by immune cells [18] independent of RBPs, 
however, a recent study has implicated the role of neutrophil extracellular trap 
(NET)-associated RNA and LL37 (RBP) in self-amplifying inflammation in pso-
riasis [19]. Herster et al., highlight an unappreciated yet potential axis involving 
neutrophils, LL37 (RBP-like) and surprisingly, RNA that are abundant in psoriatic 
as opposed to healthy skin; suggesting a novel role of NET-derived RNA-RBP 
(LL37) complexes in self-propagating inflammatory loops. Host defence peptides 
or antimicrobial peptides like LL37 can have immunomodulatory protective [20] 
or pathological roles. The dual roles are proposed to be linked to post-translational 
modifications of peptides by citrullination or carbamylation that may depend 
on the disease context and result in altered ability of antimicrobial peptides to 
bind nucleic acids, thereby compromising their immunomodulatory potential 
(reviewed in [21]). Since RNA binding proteins (like LL37 and HNRNPA1) are 
emerging as potential molecules that can rewire inflammatory circuits depending 
on the pathological context, and several RBPs are also known to regulate devel-
opmental and fibrotic pathways by interacting with spliceosome machinery and 
acting as trans- regulators of RNA processing machinery [22], we would like to 
discuss their role in driving ECM remodeling in context of cardiac fibrosis with 
particular focus on RBM20, a cardiac-specific RBP that is emerging as a global 
regulator of cardiac development and disease.
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2.  Cardiac stress induced wound healing, repair and fibrosis: patch up, 
break up or a stressed extra-matrix affair
Plethora of extrinsic or intrinsic stressors (persistent hypertension, myocardial 
infarction, neurohormonal deregulation, hypoxia, ischemia-reperfusion, pressure 
over load, drug toxicity, mechanical stretch, radiation, etc.) can result in fibrosis 
and heart failure. The cardiac myocardium is a mosaic of diverse cell types with 
overrepresentation of cardiomyocytes and fibroblasts, and moderately populating 
endothelial cells, vessel smooth muscle cells, and immune cells like tissue resident 
macrophages. The absolute proportions of the cellular components are not deter-
mined; however, lineage tracing studies have identified the above inmates in the 
myocardium of healthy heart. Cardiac wound healing following a stress-induced 
injury (resulting in development of contraction bands, mitochondrial calcification 
and membrane disruption) involves a sequalae of pro-inflammatory, anti-inflam-
matory, and reparative events and majorly resulting in cardiomyocyte death and 
functional decline. Concomitantly, the neighboring fibroblasts in the myocardial 
niche act as central nodes to drive aberrant wound healing, ECM (extracellular 
matrix) remodeling and fibrosis. The continuum of tissue homeostasis, repair, and 
fibrosis is not appreciably understood, however, the inherent plasticity of fibro-
blasts and existence of pro- and anti- inflammatory, and pro-fibrogenic polarizing 
fibroblast phenotypes suggests a cardinal role of these cells in cardiac regeneration 
and repair. The most challenging aspect of cardiac remodeling is the recreation 
and restoration of qualitatively (structurally and functionally), and quantitatively 
compliant ECM, which is pro-regenerative or anti-fibrotic. It is known that exten-
sive ECM deposition in the myocardial infarct can result in arrhythmias, however 
repopulating the native ECM following destruction is an absolute requirement 
for maintaining optimal tension in a highly contractile organ like heart. Fibrosis 
is projected to be the major player behind compromised myocardial compliance 
resulting in altered contraction-coupling events, reduced ventricular filling, 
decreased cardiac output and arrhythmias. End-stage heart failure and cardiac 
arrhythmia happen to associate with fibrosis, which is triggered as a compensatory 
response to counteract tissue damage, however, perpetuating cycles of stress and 
inflammation may result in decompensatory fibrosis and organ-failure during late-
stage pathologies marked by recalcitrant accentuating cellular stress and catenating 
chronic inflammatory loops. Cardiac fibrosis is common in several cardiac diseases 
including atrial fibrillation, hypertrophic cardiomyopathy (HCM), dilated car-
diomyopathy (DCM), and heart failure with preserved ejection fraction. Aberrant 
extracellular matrix remodeling can be present in myocardial ischemia and infarc-
tion as seen in ischemic (imbalanced oxygen supply and demand) heart diseases 
caused by atherosclerosis of the epicardial coronary arteries, and nonischemic heart 
diseases like aortic stenosis, diabetic cardiomyopathy, hypertensive heart disease, 
and hypertrophic cardiomyopathy, in which myocardial interstitial fibrosis results 
in adverse ventricular remodeling. Hypertrophying of ventricular cardiomyocytes is 
an initial adaptive response to compensate for cardiac over load and restore normal-
ization of cardiac output by balancing ventricular wall stress, however, persistence 
of stress/stressors eventually culminates in cardiomyocyte death, fibroblast acti-
vation into myofibroblast, deposition of aberrant ECM, interstitial fibrosis, and 
adverse cardiac remodeling [23, 24].
Fibroblasts are key players in the secretion, deposition, organization and 
regulation of ECM turnover, however, their phenotypic heterogeneity, functional 
diversity, and attendant signalling pathways that modulate fibrotic over regenera-
tive repair in cardiac diseases remain largely indecisive [25–37]. The sphingosine 
1-phosphate (S1P) signaling pathway is a hot spot in research for fibrotic diseases 
5
The Cellular Stress Response Interactome and Extracellular Matrix Cross-Talk during Fibrosis:…
DOI: http://dx.doi.org/10.5772/intechopen.95066
involving lung, liver, and heart [29], and improved understanding of its cross-talk 
with fibroblasts is in progress as the attendant pathways are still controversial. 
Therefore, improved understanding of the molecular mechanisms and cross-talk 
underlying fibroblast activation and cardiomyocyte death are central for restor-
ing cardiac homeostasis, designing novel regenerative approaches and developing 
anti-fibrotic therapies. Given the close association underlying tissue repair and 
fibrosis, it is intuitive that the balanced participation of common mediators can 
drive regeneration as opposed to skewed responses that may result in fibrosis. 
However, what are these checks and balances and how do they determine differ-
ential outcomes (homeostasis, repair or fibrosis) is the major challenge in the field 
of treating fibrosis or regenerating cardiac tissues in vitro. Delineating the subtle 
mechanisms and cellular, molecular, and extracellular matrix players implicated in 
regenerative and non-regenerative hearts can provide insights into the homeostasis-
repair-fibrosis continuum, which remains the most vexing challenge in developing 
successful regenerative/anti-fibrotic approaches for fibrotic disorders. Further, the 
refractory response of cardiomyocytes to complete cell-cycle progression through 
mitosis limits their self-renewal, therefore, cardiomyogenic approaches to treat 
heart failure remain practically intractable [38–48].
3.  Abortive cellular homeostasis rebalancing in cardiac fibrosis: a 
tragedy behind the broken heart
Cardiomyocytes being post-mitotic senesce with age and create cellular stress 
induced pool of biological waste over the course of ageing favoring late onset of 
fibrotic cardiomyopathies (acquired and inherited). Therefore, ageing and pro-
fibrotic gene inheritance serve as additional “self-contained spontaneous stressors” 
that can impair the cellular homeostatic autophagic machinery, which is indispens-
able for cardiac tissue repair and proteostasis rebalancing [49–52]. Regulation of 
autophagy pathways are strongly implicated in liver, lung, heart, kidney and cystic 
fibrosis, which suggests that autophagy is a potential target for the treatment of 
chronic multiorgan fibrotic diseases involving aberrant extracellular remodeling 
[53]. The divergent homeostatic pathways converge to counter cellular stress or 
clear the stressor by intersecting and coordinating with precision, therefore, the 
intersection points, interacting partners and regulatory nodes are under extensive 
research. Molecular and cellular players driving homeostasis rebalancing in diverse 
diseases including fibrosis are continuing to emerge and recently reported for endo-
plasmic and mitochondrial stress pathway networks [54–56]. Mitochondria and 
endoplasmic reticulum (ER) in cardiomyocytes are overrepresented organelles to 
co-ordinate the increased metabolic demands and maintain active calcium stores for 
smooth flow. Endoplasmic reticulum and mitochondria quality control circuits are 
also integral to cardiac function, and deregulation of these pathways are strongly 
implicated in cardiac diseases including heart failure [57–63]. ECM remodeling 
is emerging to coincide with metabolic rewiring in cardiomyocytes and matrix-
guided control of mitochondrial function in cardiomyocytes is seen as a potential 
therapeutic target in cardiac fibrosis, repair, regeneration and tissue engineering 
[64]. A recent trend in increasing ribosome profiling studies has stratified quality 
control checks that provide additional fidelity by clearance of defective messenger 
RNAs under ribosome associated quality control [65]. A genetic locus for cardiac 
hypertrophy that has been associated with alterations in stoichiometric translation 
rates of sarcomeric proteins has recently been defined [66]. Pro-fibrotic transla-
tionally regulated genes underlying cardiac fibrosis with proline (amino acid rich 
in collagen) codon usage promoted collagen synthesis emphasizing the importance 
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of translational rates that may be heightened in failing hearts that select for codon 
biasing for profibrotic genes [67].
Importantly, the stress pathways gradually converge, overlap and cross-talk with 
RNA metabolic, and sterile inflammatory pathways through processing, secretion, 
and regulation of DAMPS (danger associated molecular patterns) generated in 
response to heralding stress and inflammation. DAMPs include diverse endogenous 
host-derived molecules (extracellular ATP, histones, HMGB1 chaperons, etc.), 
which can be sensed by innate immune receptors [17] owing to their cellular/
extracellular mis-localization, stress induced modification or overexpression related 
conformational anomalies. DAMPs are primarily released by damaged and dying 
cells to facilitate sterile inflammation, which is important for tissue repair and 
regeneration, however, if left unchecked they can result in of numerous inflam-
matory diseases, metabolic disorders, neurodegenerative diseases, autoimmune 
diseases, cancer and fibrosis. Recently TGF-β has been proposed as an inducible 
DAMP that activates mechanotransducing pathways resulting in self-perpetuating 
loops leading to activation of myofibroblasts in diverse pathologies including 
cardiac fibrosis. Sarcomere integrity and rhythmic efficiency amidst high protein 
turnover, multiple protein-protein interactions, cyclic contractions and relaxations, 
and diverse “stress-stimuli” such as pressure overload, metabolic alterations, 
oxidative stress, hypoxia, ischemia-reperfusion, mechanical stress etc. is remark-
able. However, it is also highly vulnerable to succumbing to these multiple stressors 
that can result in generation of DAMPs leading to inflammation, fibrosis and 
heart failure. The myocardium cell types express DAMP- sensing receptors and are 
proficient to respond immediately to stress and damage. Therefore, efficient quality 
control mechanism regulating cardiac homeostasis are indispensable to sarcomere 
maintenance and dynamic adaptation to stress [68–72].
4. Inflammatory networking in cardiac fibrosis: a heart on (in) flame
It is becoming increasingly recognized that the regenerative ability is not 
completely reliant on genetic makeup, environmental conditions or evolutionary 
hierarchies but the nature and extent of the immune responses to cardiac injury 
equally play important role in governing regenerative and non-regenerative modes 
of wound healing [73]. Importantly, cellular stress pathways cross- talk with 
inflammatory pathways that actively participate in restoring tissue homeostasis 
and overactivation of the inflammatory mediators can result in cardiomyocyte 
death and fibrosis. Macrophages are crucial for tissue homeostasis, following 
injury, circulating monocytes give rise to proinflammatory macrophages through 
activation mediated by DAMPs or cytokine secretion. Macrophages may contribute 
to cardiac fibrotic remodelling through secretion of TNF-α, IL-1β, IL-10, TGF-β 
and growth factors [74]. Studies have shown that Gata6 expressing macrophages 
can regulate cardiac fibrosis [75], CX3CR1+ and CCR2+ resident macrophages 
may positively or negatively regulate cardiac fibrosis, respectively following 
injury [76, 77]. Mast cells exist in low density in heart tissue, however, following 
an injury mast cells infiltrate heart tissue [78]. DAMPs may trigger degranula-
tion of mast cells that leads to the release of inflammatory mediators including 
tryptase, chymase, TNF-α, and IL-1β [79]. Tryptase and chymase activate a 
potent fibrogenic mediator i.e. TGF-β (that promote myofibroblast differentia-
tion and collagen production). Mast cells also produce PDGF-A and FGF2, which 
positively regulate fibrosis [80, 81]. However, studies have shown that mast cells 
can also produce IL-10 (anti-inflammatory agent) that is a negative regulator of 
fibrosis [82, 83]. Dendritic cells (DCs) play important role in initiating an adaptive 
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immune response in post-injury cardiac remodelling. Studies have shown that DCs 
infiltrate cardiac tissue following an injury, specifically CD11+ DCs (bone marrow 
derived) are held crucial for cardiac homeostasis. Deficiency of CD11+ DCs fol-
lowing a cardiac injury may result in enhanced fibrosis [84]. Another study had 
shown that deletion of cardiac CD103+ DCs resulted in increased fibrosis [85]. 
Adaptive T and B lymphocytes are also central to cardiac inflammation as B and T 
cells infiltrate cardiac tissue following injury. There are different subsets of T cells 
including: CD4+, CD8+, CD73+ and Tregs. CD4+ cells have been reported to produce 
proinflammatory and fibrotic cytokines like IFN-α, following injury [86], while 
CD73 expressing T cells reduced fibrosis [87]. B cells secreted proinflammatory 
cytokines like IL-1β, IL-6 and TNF have been positively associated with fibrosis 
[88]. Neutrophils are known to regulate fibrosis in context dependent manner, 
however, neutrophil-derived extracellular traps (NETs) are becoming increasingly 
implicated in fibrotic pathologies including cardiac fibrosis. NETs have recently 
gained attention in chronic inflammatory, autoimmune and fibrotic settings 
including cystic fibrosis, interstitial lung disease, thromboinflammation, hyper-
trophic cardiomyopathy and liver fibrosis (reviewed in [89–95]). Notably, NETs 
have been reported to be associated with disease-specific bioactive proteins loaded 
onto them [96]. Intriguingly, emerging clinical and experimental studies indicate 
that neutrophils are able to release intrinsically and qualitatively different NETs 
decorated with disease-specific bioactive proteins dictated by diseased inflammatory 
environment containing tissue factor, IL-1β, IL-17, and LL37, suggesting systemic 
inflammation driven transcriptional-reprogramming in circulating neutrophils, 
which triggers de novo expression of disease-specific protein fingerprints that are 
extracellularly delivered through generation of NETs [97] and references therein, 
these exciting findings implicate NETs as potential anti-fibrotic targets. The non-
immune cells of myocardial niche also participate in inflammatory responses, e.g. 
cardiomyocytes can generate pro-inflammatory mediators leading to profibrotic 
TGF-β and IGF-1 signalling [98, 99]. Endothelial cells can serve as both positive 
and negative regulator of fibrosis by generating profibrotic mediators like TGF-β, 
FGFs, or endothelin-1 [100] and undergoing endothelial to mesenchymal transi-
tion [101]. Endothelial cells express HIF-1 (hypoxia inducible factor) that can have 
anti-fibrotic effects [102] endothelial CXC chemokine Interferon-gamma-inducible 
protein (IP)-10/CXCL10, is also an anti-fibrotic molecule [103, 104].
The key observations that reflected elevated circulating proinflammatory 
cytokines in heart failure with reduced ejection fractions pumped the research into 
exploring role of immune system in heart failure pathogenesis. If inflammation is 
the cause or result of heart failure is still debatable, however, the developments in 
understanding the roles of innate and adaptive immune cells in heart failure are 
in active progress to identify heart failure patients who can have a cardio-inflam-
matory phenotype and can receive prospective anti-inflammatory and immuno-
modulatory regimens. The CANTOS trial with anti- IL-1β antibody canakinumab 
indicated decreased hospitalization rates in certain group of heart failure patients 
[105], these findings have renewed the interest in decoding cardio-inflammatory 
pathways for therapeutic targeting. Sensing of DAMPs can trigger non-cellular 
and cellular effectors in including IL-1, IL-6, IL-8, TNF, chemokines, complement 
system, inflammasome assembly, and activation of neutrophils, monocytes, macro-
phage innate immune cells that further engage the adaptive immune arm to trigger 
inflammatory loops [106]. Leukocyte dependent regulation of cardiac fibrosis is an 
ongoing area; however, it stays controversial and warrants further studies to exploit 
leukocyte plasticity and heterogeneity in cardiac fibrosis therapeutics [107]. Recent 
demonstration of engineered T cells or the CAR T-cell therapy directed against acti-
vated fibroblast specific antigen has sparked new hopes to existing limited clinical 
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interventions and therapies in fibrotic heart failure [108, 109]. A recent study has 
demonstrated that macrophages expressing Mertk immune receptor in the heart 
supports cardiomyocyte health by phagocytosing exopher particles ejected from 
stressed cardiomyocytes harboring defective mitochondria. Mertk facilitated 
defective elimination of mitochondria from the myocardial tissue and prevented 
activation of the inflammasome, autophagy, metabolic stress, and ventricular 
dysfunction [110]. IL-11 signaling is also implicated in cardiac and cardiorenal 
fibrosis, however further studies will better indicate its precise role in driving 
pathogenesis [111]. A cross-talk between RNA processing pathways and immune- 
and non-immune cells through diverse mediators in context of cardiac fibrosis has 
been depicted in Figure 1.
5.  Messenger RNA regulatory networks may modulate cellular stress and 
inflammation driving cardiac fibrosis: a message to the heart still in 
the outbox
The global co- and post- transcriptional mechanisms implicated in cardiac 
fibrosis are not well established, however, emerging studies are geared at extract-
ing the subtle communications to identify intersection points between the cel-
lular stress regulating pathways, regulatory non-coding RNAs, RNA metabolism 
intermediates/mediators and cardiac RNA binding proteins (RBFox, HuR, MBNL2, 
PUM2, QKI, CELF1, MBNL1, PTBP1) in context of cardiac diseases including 
fibrosis [66, 112–120]. A recent study implicated NUP155 subdomain hotspot with 
enriched allelic variants of the gene that suggests important role of RNA metabo-
lism in cardiac disease and development [121].
Stem cell based regenerative approaches have found limited applicability in 
clinical translation to treat fibrosis. This ignited the research targeted at identify-
ing cell- free secretory molecules that could not only have potential anti-fibrotic/
regenerative potential to ameliorate fibrosis but characterization of these molecular 
Figure 1. 
RNA processing and modifications and their link to inflammation in cardiac fibrosis: (a) m6A Methylation, 
(b) Uridylation, (c) Editing, (d) Alternative Splicing, (e) Immunostimulatory RNA may result in Interferon 
and cytokines production. (f) Interaction between immune and non-immune cells during fibrotic remodeling. 
Diverse RNA processing pathways can result in generation of immunostimulatory RNAs that can trigger 
inflammatory cascade.
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players would also facilitate understanding of mechanisms underlying pathogenesis 
of fibrosis. In this context, bioactive vesicles/exosomes have been extensively inves-
tigated to explore the role of regulatory RNAs (generated through RNA processing 
pathways) in delivering pro- or anti- fibrotic outcomes, besides non-coding RNAs 
are also extensively studied in context of fibrosis independent of their exosomal/
vesicular loading [120–141]. The cardiac inflammatory circuits also tend to con-
verge at the regulatory networks controlled by RNA processing, metabolism and 
surveillance pathways. Particularly, the post- transcriptional regulation of cyto-
kines to stabilize mRNA, determine the strength of proinflammatory pathways. 
Altered expression of AU rich (ARE) or GU rich (GRE) elements in cytokine and 
cytokine pathway intermediate transcripts impairs mRNA decay and can result in 
heightened immune responses as seen in diseased states [142]. Immunostimulatory 
RNAs (like double stranded RNAs) generated through deregulated RNA processing 
pathways along with RNA binding proteins of RNA helicase (RNA sensors) fam-
ily are emerging as important components of immune response pathways during 
sterile inflammation that involves DAMP sensing [15, 16]. Mitochondrial quality 
control pathways intersecting with the endosomal compartments and lysosomes 
are recently reported to favor generation and release of mitochondrial-derived 
vesicles in former condition [143], further offering discernible biologically stable 
lipid vesicles that may help investigate how secreted cargos can impact tissue repair 
and homeostasis or trigger fibrosis, and can be extended to establishment of liquid 
biopsies for studying the progression of fibrotic diseases or alternatively these 
vesicles may serve as therapeutic tools like exosome-derived non coding RNAs 
[121, 125, 127, 128, 138, 139, 141, 144] circulating microRNAs (miRNAs) and tissue 
resident miRNAs play paradoxical role both as anti-fibrotic [145–148] and pro-
fibrotic [149–151].
6.  Harnessing RNA metabolic pathways in cardiac development and 
disease: getting to core of the heart
The cardiac output is tightly tuned to the functional outputs of the cardiac 
transcriptome or faithful expression of cardiac-specific genes. It is becoming 
evident that cellular processes (that are linked to generation of RNA variants) 
including alternative splicing, RNA editing, epitranscriptomic modifications like 
methylation, and alternative polyadenylation [152] have a major role in shaping the 
cardiac adaptive responses [119]. The advent of high throughput NGS sequencing 
has revealed striking diversity in RNA species/variants/isoforms that have revolu-
tionized the field of RNA biology by informing on the codes of burgeoning RNA 
inventory, which has now been exploited in context of functional relevance of the 
neo-RNA entities in context of physiological and pathological outcomes. Expanding 
information and identification of genetic markers for heterogeneous complex 
diseases like heart failure has made it appreciably evident that cardiac develop-
ment and differentiation cues are under tight regulation of splicing events [153], 
and mis-splicing of certain genes like titin (TTN) that is implicated in contractility 
and mechanosensation can result in adverse cardiac extracellular remodeling and 
fibrosis. Interestingly, single cell RNA sequencing of cochlear hair cells recently 
documented unappreciated complexity in splicing diversity and isoform abundance 
underlying biology of hearing and deafness, and reported sorcin (a key player in 
cardiac excitation-contraction) as a top hit in cochlear outer hair cells [154]. These 
exciting findings reflect potential shared mechanosensory targets that could result 
in co-manifestation of heterogenous genetic disorders like heart failure and hearing 
loss, which involve electrical conductance and contraction events (it remains to be 
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explored if sorcin may have isoformic pattern of expression). It is already known 
that cardiac arrhythmias are a feature of Jervell and Lange-Nielsen syndrome 
(JLNS), an autosomal recessive disorder associated with congenital profound 
sensorineural hearing loss arising from homozygous or compound heterozygous 
mutations in either KCNQ1 or KCNE1 subunits of potassium ion channel conduct-
ing the slow component of the delayed rectifier current [155, 156].
Constitutive RNA splicing primarily involves the spliceosome machinery acting 
at the splice sites, however, alternative splicing may differ in its mechanism of 
action by engaging further cis- elements (regions within pre mRNA besides 5’/3’ 
splice sites) like enhancers of exon/intron splicing [157]; the cis-elements are 
further acted upon by trans- acting modulators that constitute a family of RNA 
binding proteins (RBPs) with RNA binding motif (RBM), which further regulate 
negatively (repress) or positively (activate) the splice site selection. The activators 
include serine/arginine-domain–containing (SR) proteins and SR-related factors 
that dictate binding and assembly of the spliceosome complex and decide differ-
ential inclusion of exons in the mature transcript [158]. In contrast, the repressor 
trans-elements include the family of heterogenous nuclear ribonucleoproteins 
(hnRNPs) that tend to suppress splice site recognition [159, 160]. Therefore, 
alternative splicing events diversify the overall repository of functional and/or 
regulatory genes by inclusion/exclusion of exon, intron retention, alternative 5’ or 
3’ splicing, and mutually exclusive exon utilization [119, 152], and at the same time 
splicing diversity may reflect pathological vulnerabilities dictated by the inherited 
variants that offer isoformic switching.
7.  RBM20 interactome in cardiac development and disease: determining 
the soft- or hard- heartedness
Cardiac diseases including cardiomyopathy and arrhythmia are long known to 
be regulated by isoformic pattern of protein expression for genes including titin 
[161], CAMK2D, LDB3 and CACNA1C [162, 163]. Titin isoform-switching mecha-
nisms at RNA (alternative splicing) and protein (post-translational modification) 
levels, which direct titin-based passive tension tuning remained largely elusive 
[164–169]. RNA binding protein RBM20, which is a splicing related factor was 
known to steer various aspects of cardiac function by regulating genes involved in 
biomechanics (TTN and TPM1), ion homeostasis and electrical activity (CAMK2D 
and CACNA1C) and signal transduction (CAMK2D and SPEN). Titin is the best 
exemplified target of RBM20 and TTN mutations are vastly implicated in cardio-
myopathy [170, 171], and cardiovascular diseases [164, 172–174]. However, the 
mechanisms underlying alternative splicing of titin and role of thyroid hormone 
and insulin signaling in regulating it were nearly correlative [175–178] as the splice 
factors regulating alternative splicing in titin remained undetermined until early 
this decade. The role of post-transcriptional regulation in cardiac function and 
pathogenesis of human heart failure gained impetus following a pioneer study [179] 
on RNA binding motif (RBM20) protein, which has now emerged as a global regu-
lator of cardiac alternative splicing isoformic switch in protein titin. RBM20 was 
found to be predominantly expressed in striated muscle, with maximum expression 
in the heart and its deficiency in rats was reported to resemble the pathophysiology 
of genetic dilated cardiomyopathy (fibrotic remodeling in heart). The RBM20-
null rats exhibited increased subendocardial fibrosis with age and this effect was 
accompanied by electrical abnormalities and sudden death. The reduced activity of 
RBM20 (due to mutations/variants) resulted in altered isoform expression of genes 
central to biomechanics, electrophysiology and signal transduction culminating in 
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cardiomyopathy, fibrosis, arrhythmia and sudden death [179]. Following these sem-
inal findings that delineated the role of RBM20 driven splicing in titin isoforms, the 
ribonucleoprotein RBM20 has now paralled the role of titin in regulating structural 
and functional characteristics of cardiac development and disease. Cardiac-specific 
splicing events are attributed to RBM20, and recent studies with defective RBM20 
variants have been shown to be associated with cardiac transcript variants resulting 
in cardiomyopathy including DCM (dilated cardiomyopathy) [180–190].
Structurally, RBM20 is a 1227 amino acid long protein with a leucine-rich 
N-terminal domain, zinc finger (ZnF) domain 1, RNA recognition motif (RRM) 
followed by mutational hotspot arginine-serine (RS) rich domain, glutamate (E) 
rich and ZnF2 regions located towards C-terminal. RRM and RS regions, and 
phosphorylation within RS region, are reported to be crucial for nuclear localiza-
tion [179, 191, 192], RRM is important for binding to “UCUU” RNA sequence 
that dictates RBM20 binding to target genes. Several mutations are reported in RS 
region (predominantly the RSRSP stretch, amino acids 634-638) that likely disrupt 
its nuclear localization and hence splicing of target genes like titin, subsequently 
resulting in adverse cardiac modelling and familial dilated cardiomyopathy with 
associated fibrosis [148, 183, 193–203]. Compared to nuclear localization regions, 
the structural components contributing to splicing activity of RBM20 towards its 
targets are not fully explored, the near C-terminal E region has shown to have some 
contributions to splicing though [179, 204]. RBM20 is known to interact with spli-
ceosome complex subunits U1 and U2 (small nuclear ribonucleic particles) and U2 
related proteins like U2AF6 and U2AF35 [205]. The inventory of RBM20 regulated 
cardiac pre-mRNAs is dynamic and includes the following validated genes in human 
and rat- titin (TTN), calcium voltage gated channel subunit α1 C (CACNA1C), 
calcium/calmodulin dependent protein kinase II delta and gamma (CAMK2D 
and CAMK2G), formin homology 2 domain containing 3 (FHOD3), Lim domain 
binding 3 (LDB3), Lim domain only protein 7 (LMO7), muscular-enriched A type 
laminin-interacting protein (MLIP), PDZ and LIM domain 3 (PDLIM3), reticulon 
4 (RTN4), ryanodine receptor 2 (RyR2), SH3 domain containing kinase binding 
protein 1 (SH3KBP1), sorbin and SH3 domain containing protein (SORBS1), and 
triadin (TRDN) [153, 179, 205–208].
Titin is an integral sarcomere protein responsible for maintaining passive 
elasticity in heart, structurally it is organized into modular structure with immu-
noglobulin-like (Ig), fibronectin type III (FnIII), proline (P), glutamate (E), valine 
(V), and lysine (K) containing highly elastic I-band region. The N-terminal domain 
of titin anchors it to the sarcomeric Z-band and C-terminal domain embeds it into 
M-band. The A-band maintains rigidity during contraction by binding to myosin. 
Titin’s structural integrity is central to normal cardiac function, maintaining passive 
tension and driving length-dependent activation/Frank-Starling effect. Besides 
providing mechanical properties, titin stretching also participates in cellular 
signaling that facilitates cardiomyocyte growth and might be implicated in chronic 
myocardium remodeling, hypertrophy and fibrosis. Cardiomyopathy patients with 
mutations in titin gene further demonstrate the contribution of titin to systolic 
and diastolic heart failure. Systolic dysfunction underlies dilated cardiomyopathy 
(dilation of left ventricle) and hypertrophic cardiomyopathy (myocardial hypertro-
phy and ventricular thickening). Diastolic dysfunction is a hallmark of restrictive 
cardiomyopathy with preserved contractile force, however, abnormal relaxation 
during diastole results in decreased cardiac output due to inappropriate ventricle 
filling. Truncation mutations in titin gene cause dilated cardiomyopathy through 
diverse pathways that involve haploinsufficiency, activation of mTOR energy 
sensor pathways and increased metabolic stress (recently reviewed in [209]). 
Human induced pluripotent stem cell (hiPSCs) culture models aimed at generating 
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cardiomyocytes from titin mutation carrying patients depict disorganized sar-
comeric array, contraction disability and impaired force generation, however, 
similar extent of sarcomeric damage and myofibril contraction impairment has 
not been recapitulated in human studies or biopsied cardiomyocytes from titin 
variant patients. Therefore, it is alternatively proposed that titin variants may 
operate through creating a metabolic stress that could impair cardiac function 
independent of mutation sites by altering RNA metabolism pathways triggering 
non-sense mRNA decay (NMD) of abnormal titin variants and development of 
DCM phenotype. The cardiac metabolism could switch to branched chain amino 
acid pathway in place of fatty acid metabolism, deregulation of mTOR and 
autophagy pathways [210–218].
RBM20 cardiomyopathy has high penetrance and correlates with increased rates 
of heart failure, arrhythmias, and sudden cardiac death, new insights into RBM20 
cardiomyopathy are extensively discussed recently [190]. Given the large size of titin 
(near 300kb) it is known to undergo extensive splicing events and yield several titin 
isoforms with cardiac N2B and N2BA to be the best characterized. N2B (shorter and 
stiff isoform) and N2BA (longer and pliant isoform) are adult cardiac isoforms of 
titin that regulate passive stiffness in the heart, and this is attributed to their struc-
tural dissimilarity in the highly elastic I-band region. Alternative splicing variants of 
titin during cardiac development keeps selecting for the shorter and stiffer isoform 
N2B in course of fetal to adult cardiac development, and physiologically N2B is 
overexpressed as compared to pliant N2BA isoform. However, aberrant expression 
patterns of titin isoforms resulting in altered ratios of N2B and N2BA are associated 
with cardiac diseases including cardiomyopathy with fibrosis and heart failure. 
RBM20 is shown to facilitate exon skipping events thereby selecting for shorter and 
stiffer forms of titin over development. In animal models, RBM20 homozygous 
mutations show increased ratio of N2BA/N2B (mirroring DCM phenotype), induced 
expression of RBM20 in RBM null mice decreases this ratio, however, intermediate 
effects (titin length, passive tension, sarcomere length) are seen in heterozygous 
mutations, indicating quantitative modulations of RBM20 as potential therapeutic 
approach to treat cardiac diseases [153, 179, 183, 194, 219]. RBM20 mutations in 
human patients result in severe inherited early onset DCM, manifesting even early 
on in younger patients with sudden death [190, 220]. Patient-specific stem cell based 
hiPSC culture models or CRISPR/CAS9 gene editing tools have been exploited to 
measure the effect of RBM20 point mutations in cardiomyocytes and alterations in 
sarcomere length, calcium handling, electrical coupling have been reported. The 
human iPSCs containing RBM20 mutations offer great tractable and tunable system 
to model cardiomyopathy in vitro and investigate potential signaling pathways con-
tributing to the pro-fibrotic phenotypes [189, 221, 222]. The paradigm-shift in RNA 
metabolism associated interactome has begun to offer new therapeutic windows 
by unravelling the novel RNA binding proteins and splicing factors in context of 
cardiac development and fibrotic cardiomyopathies [119]. Biogenesis of regulatory 
non-coding RNAs i.e. microRNA, long noncoding RNA, and circular RNA, and their 
role in cardiac fibrosis, and RBM20 mediated alternative splicing of titin pre-mRNA 
is shown in Figure 2.
We briefly discuss the inflammatory networks in upper airway fibrotic diseases 
like laryngotracheal stenosis and subglottic stenosis that are relatively less explored 
in terms of mechanisms of fibrotic pathways, however, these pathologies need 
special attention as they might affect increasing number of patients given the cur-
rent COVID-19 pandemic. Recent reports show that COVID-19 critically ill patients 
need mechanical ventilation, and many of these patients who need prolonged 
ventilation need surgical tracheostomy that is implicated in development of upper 
airway fibrosis.
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8.  Laryngotracheal stenosis: the pathogenesis and inflammatory 
pathways
Laryngotracheal stenosis (LTS) is an abnormal wound healing process of 
laryngotracheal mucosal inflammation, wound healing and scar formation. LTS 
is a fibrotic disease leading to pathologic narrowing of the larynx, subglottis, and 
trachea (the upper airway). There can be multiple etiologies to LTS, ranging from 
intubation injury (iatrogenic), radiation, autoimmune disease, to idiopathic [223]. 
The early stages of LTS are marked by dysphonia and communication difficulties 
that can develop into life-threatening progressive dyspnea leading to the airway 
compromise [224]. The most common form of LTS is the iatrogenic LTS (iLTS) 
caused by regional hypoxic and ischaemic pressure (stress) induced necrosis of the 
airway following prolonged intubation or tracheostomy [225]. The possible patho-
physiology behind iatrogenic LTS is the surpassing of the pressure exerted by the 
cuff while prolonged intubations to that of the mucosal capillary perfusion pressure 
(approx. 35 mmHg), which results in ischemia, inflammation of the mucosa, and 
subsequent fibrotic strictures [226, 227]. The airway is primarily formed of 3 sets of 
cell types including epithelial cells, the fibroblasts, and the resident immune cells. 
The cross-talk of fibroblasts, immune cells and inflammatory cytokines participates 
in the development and propagation of LTS.
9. Inflammatory networks in the pathogenesis of LTS
TGFβ-SMAD2/3 cascade has been implicated in LTS and TGF-β antagonists have 
shown to attenuate fibrosis, however, TGF-β3 isoform has been reported to have 
antifibrotic response in LTS healing by significantly decreasing the inflammation 
and collagen deposition [228, 229], indicating opposing roles for isoforms of TGF-β. 
Hypoxia induced expression of IL-6 plays an important role in the pathogenesis of 
Figure 2. 
Biogenesis of regulatory non-coding RNAs i.e. microRNA, long noncoding RNA and circular RNA and 
their role in cardiac fibrosis (a-c). Fate of aberrant RNA transcripts (d). RBM20 dependent splicing of 
Titin pre-mRNA resulting in formation of Titin isoforms which regulate cardiac development and fibrosis. 
Abbreviations: miRNA: microRNA; lnRNA: long non-coding RNA; cirRNA: circular RNA; NMD: nonsense-
mediated decay; NSD: nonstop-mediated decay; NGD: no-go decay
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LTS, the pressure exerted by the endotracheal tube cuff causes hypoxic and isch-
emic necrosis of the laryngotracheal mucosal tissue leading to inflammation and 
scarring marked by increased expression of IL-6, α-SMA & collagen, importantly 
IL-6 and myofibroblasts were also increased in an ex-vivo culture of healthy tracheal 
fibroblasts cultured under hypoxic conditions [230]. Possible role of B or T-cells in 
the formation of granulation tissue has also been been suggested [231]. Increased 
expression of profibrogenic Th2 cytokine IL-4 was seen in the brush biopsy samples 
of LTS scar and it stimulated fibroblast activation and excessive collagen formation 
in the LTS wound [225]. The expression of another Th2 cytokine IL-13 appeared 
to follow the same expression pattern of IL-4 and resulted in excessive fibrosis 
[232]. In contrast to Th2 cytokines, the Th1 cytokine IFN-γ inhibited fibrosis in LTS 
patients. Subsequent studies have shown the impact of IFN-γ on the LTS fibroblasts 
as significant decrease in levels of collagen and TGF-β expression was reported 
in the IFN-γ treated human LTS-derived fibroblasts compared to the untreated 
LTS-derived fibroblasts and normal laryngotracheal fibroblasts [226]. Dysregulated 
functioning of macrophages is related to fibroproliferative LTS [232], a prolonged 
cytokine signalling in the form of IL-4/IL-13 by Th2 cells can also contribute to 
impairment of macrophages by switching the non-fibroproliferative “classically 
activated” M1 macrophages into the fibroproliferative “alternatively activated” M2 
macrophages [232]. Mice LTS model of chemical and mechanical injuries showed 
increased expression of M2 cell surface marker CD206 [224]. Inflammatory cyto-
kine expression study in iLTS and autoimmune LTS patients demonstrated elevated 
levels of the macrophage growth factor granulocyte macrophage colony-stimulating 
factor (GM-CSF) and M2 cytokine IL-10 than that in controls [233]. Fibroblasts 
are the mesenchymal cells which are not terminally differentiated and rest in 
inactive state, under homeostasis. In their inactive but normal state they localise 
to the subepithelial layer of the airway tissue and provide for the biochemical and 
mechanical support to the tissue [234]. However, studies have reported increased 
ECM production and migration, and reduced contraction of iLTS fibroblasts [235], 
moreover, studies involving use of beta-aminopropionitrile (βAPN), an inhibitor 
of collagen cross-linking also demonstrated enhanced profibrotic features (overex-
pression of collagen I and II) in iLTS-derived fibroblasts [236], metabolically they 
exhibited enhanced glycolysis to oxidative phosphorylation ratio as see in prolifera-
tive cancer cells, justifying highly proliferative nature of iLTS-derived fibroblasts 
[237]. Emerging studies are reporting genetic link to LTS pathology, suggesting 
alternative treatment approaches to cure this fibrotic pathology. A functional single 
nucleotide polymorphism of TGF-β1 located in a negative regulatory element of its 
promoter was associated with the iatrogenic LTS. The data identified protective and 
susceptible genetic loci in patients undergoing endotracheal intubation. Another 
study, focused on 3 candidate genes encoding the innate immune receptor CD14, 
matrix metalloproteinase-1 (MMP-1), and the cytokine transforming growth factor 
β1 (TGF- β1). Reported association between MMP-1 and susceptibility to iLTS fol-
lowing intubation merits further investigation in a lager patient cohort [238].
10.  Subglottic stenosis: a complex interplay between inflammation and 
fibrosis
Subglottic stenosis (SGS) is a relatively less explored fibrotic pathology in terms 
of mechanistic insights on inflammatory pathways. Researchers have gathered 
information to some extent by evaluating the changes that occur in the airway as a 
result of obliterative bronchiolitis [239], which shares the same fibrotic features of 
subglottic stenosis as studied in a murine model with emphasis on cytokines such 
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as IL-1β, TGF-β and prostaglandin PGE2 [240]. SGS is accompanied by an acute 
and an exaggerated inflammatory response that triggers a shift in the cellular and 
molecular components in the healing wound in favor of more fibroblastic etiology 
[235]. SGS has numerous potential etiologies of which the most common cause in 
adults and children alike is prolonged endotracheal intubation. With developments 
in intensive care and associated intubations, it is natural that iatrogenic stenosis will 
become a major factor affecting post ICU quality of life. Animal and human studies 
have shown an upregulation of inflammatory markers in stenotic tissues. Patient 
factors like increased BMI, diabetes mellitus and chronic laryngopharyngeal reflux 
have also been implicated as causative factors for development of subglottic stenosis 
[241]. Cytokines like IL-1β, IL -10, TNF α, IFN γ and GM-CSF have shown signifi-
cant increase in subglottic stenosis specimens [226]. Enhanced expression of profi-
brotic growth factors and cytokines like TGF-β, PDGF, IL-1, and Prostaglandin E2 
was seen in patients of healing laryngeal lesions [242]. Expression of matrix metal-
loproteinases (MMPs), α-SMA, SMADs, IL-1 continued to rise 3 weeks beyond the 
initial insult [231]. Therefore, it appears that SGS undergoes an aberrant healing 
response as cytokines corresponding to various stages of wound healing process 
including inflammation (IL-1, TGFβ), proliferation (SMADs, TGFβ), and matura-
tion (MMPs, αSMAs) are reported to present in pathogenesis of SGS. Idiopathic 
subglottic stenosis (iSGS) also has an inflammatory network evident from various 
studies suggesting the role of γδ T cells in IL-17A dependent tissue inflammation 
and airway remodeling in iSGS. Further studies delineating the role of RNA biology 
pathways might open up viable therapeutic options for this devastating pathology.
11. Future perspectives and summary
We are encouraged to chase the role of RBPs in homeostasis-tissue-repair-
fibrosis continuum based on our recent preliminary findings, where we report for 
the first time an in vitro model that rigorously recapitulates proteolytic stress (as 
encountered in fibrotic pathologies) induced stress granule (SG) biomolecular 
condensate-like proteome signatures [243]. Dynamic phase separated membrane-
less organelles including SGs are induced upon varied stress-stimuli (infectious or 
non-infectious) and are implicated in spatiotemporal control of various cellular 
functions including formation of signalling complexes, clustering of vesicles, 
sorting and trafficking of cargo [244]. Phase separated biomolecular condensates 
are becoming increasingly linked to developmental and pathological pathways 
[245–249]. We proposed proteases as novel stressors that can have diverse outcomes 
when present at varying concentrations (protease-antiprotease balance is crucial for 
driving tissue repair or fibrotic phenotypes). We observed heightened ribonucleo-
proteins (RNPs), spliceosome machinery, regulatory RNA generating proteins, and 
RNA binding proteins (RBPs) in our high-throughput proteomics data [243]. The 
formation of SGs like proteome was concomitant to translational halt in major-
ity of proteins, sparing few essential cytoprotective proteins including exosome 
biogenesis and secretory pathway proteins that undergo synthesis despite stress 
environ. We hypothesize that the unique stress-associated proteins that represent 
“stress-essentialome” might get packaged and enriched into exosome vesicles in 
addition to the hitchhiking of SG regulatory RNAs, RBPs, RNPs and cytoprotective 
proteins onto the exosomal carriers leading to conglomeration of unique disease/
stressor-specific cargos in exosome silos. Translational halt would result in poly-
some run off and dissociation of ribosome and translating mRNAs that would 
partition into the stress granules, therefore, RNA and polysome profiling of stressed 
cells in addition to exosome cargo profiling might offer valuable information on 
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pathologic transcripts, associated regulatory RNAs (miRNAs, lncRNA) and trans-
lating ribosome composition besides the proteome signatures, thereby offering new 
dimensions to investigate stress-induced regenerative or fibrotic responses and the 
role of RNA processing machinery and RBPs in driving these triggers. It might offer 
identification of cell or tissue specific splicing factors and an opportunity to attempt 
rescuing splicing related alterations inherited in genome (pathogenic variants), to 
switch for native isoforms. In addition, stress-induced secretion of extracellular 
vesicles/exosomes could offer novel therapeutic opportunities by developing liquid 
biopsies in fibrotic diseases (a less explored area), which may yield meaningful 
information and help predict progression of the disease in suitable disease-specific 
in vitro models. Exosomes are relatively stable, can avoid background noise, can be 
easily detected from blood and their molecular analysis may decipher pathobiol-
ogy of disease, fibrotic liver derived exosomes (in mice) showed increased CCN2; 
decreased Twist1, miR-214 than control mice [250]. Circulating exosomes from 
mice with alcohol related liver disease when transmitted to normal mice resulted in 
pro-inflammatory/fibrogenic liver phenotype [251]. MiR-125 has also been found to 
be upregulated in serum from patients with cirrhosis than controls [252]. Multiple 
studies in-vitro and in mice have revealed pathologic micro-RNAs associated with 
liver injury, liver fibrosis and liver malignancy [250]. However, major challenge 
in translating bench to bedside knowledge include reliable standardization and 
Figure 3. 
Proposed model for cellular stress induced biological condensates that can regulate homeostasis, 
tissue repair and fibrosis. A cellular-stress induced reshaping of RNA processing machinery by generation 
of biomolecular condensates, and their coupling to mitochondrial and exosomal pathways. The stress-coupled 
exosomes are proposed to carry pathologic cargo which can be exploited to develop liquid biopsies in the context 
of fibrotic disorders. The expression of cardiac-specific RBPs in our model can be utilized to develop cardiac 
regenerative approaches in vitro or to study the role of RBPs in cardiac fibrosis. RNPs: ribonucleoproteins: 
RBPs: RNA binding proteins; CBC: cap binding complex; EJC: exon junction complex; SERBP1: SERPINE1 
mRNA-binding protein 1; PAI-1: Plasminogen activator inhibitor-1; ISG: Interferon stimulated gene; PRKRA: 
Protein kinase, interferon-inducible double stranded RNA dependent activator; ADAR: Adenosine deaminases 
acting on RNA; EF2AK2: Eukaryotic Translation Initiation Factor 2-alpha Kinase 2; RED color: upregulated 
proteins; MT: mitochondrion; CPT: Carnitine palmitoyl-transferase; MPC: mitochondrial pyruvate carrier; 
PDC: Pyruvate dehydrogenase complex; ACAD: Acyl-CoA dehydrogenase; ACAA2: acetyl-Coenzyme A 
acyltransferase 2; BCKDHA: branched-chain alpha-keto acid dehydrogenase; NDUFS: NADH-ubiquinone 
oxidoreductase subunit; SDHAF: Succinate dehydrogenase complex assembly factor 1; UQCRB: Ubiquinol-
cytochrome c reductase binding protein; SCO: synthesis of cytochrome c oxidase; TOM: translocase of the 
outer membrane; TIM: translocase of the inner membrane; ETC: electron transport chain. DAMPs- danger 
associated molecular patterns.
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characterization protocols, and validation in a well-characterized patient popula-
tion. Therefore, we are interested in deciphering the molecular information stored 
in exosomes of patients with liver cirrhosis using standardized protocol and their 
correlation with key events like death, sepsis, organ failures. Our proposed model of 
stress- induced reshaping of RNA metabolic pathways that are coupled to mito-
chondrial alterations and exosome biosynthesis is shown in Figure 3.
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